$0.47
0.00%
Nasdaq, Tue, Aug 12 2025
ISIN
US0537342083
Symbol
AVGR

Avinger, Inc. Stock price

$0.47
+0.00 0.00% 1M
+0.01 3.04% 6M
-0.34 42.05% YTD
-0.63 57.10% 1Y
-25.63 98.18% 3Y
-166.12 99.72% 5Y
-1,957,199.53 100.00% 10Y
-1,619,999.53 100.00% 20Y
Nasdaq, Closing price Tue, Aug 12 2025
+0.00 0.00%

Key metrics

Basic
Market capitalization
$1.6m
Enterprise Value
$-160.0k
Net debt
positive
Cash
$5.9m
Shares outstanding
2.8m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
0.2 | 0.2
EV/Sales
negative | negative
EV/FCF
0.0
P/B
0.4
Financial Health
Equity Ratio
-45.0%
Return on Equity
295.4%
ROCE
-426.8%
ROIC
-
Debt/Equity
1.1
Financials (TTM | estimate)
Revenue
$7.3m | $7.3m
EBITDA
$-17.2m | -
EBIT
$-17.5m | $-17.2m
Net Income
$-17.4m | $-13.3m
Free Cash Flow
$-14.6m
Growth (TTM | estimate)
Revenue
-6.3% | -4.0%
EBITDA
-10.4% | -
EBIT
-10.5% | -3.7%
Net Income
6.7% | 27.4%
Free Cash Flow
-5.5%
Margin (TTM | estimate)
Gross
20.9%
EBITDA
-236.5% | -
EBIT
-241.0%
Net
-239.0% | -181.1%
Free Cash Flow
-200.4%
More
EPS
$-7.8
FCF per Share
$-5.2
Short interest
4.5%
Employees
71
Rev per Employee
$110.0k
Show more

Is Avinger, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Avinger, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Avinger, Inc. forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Avinger, Inc. forecast:

Buy
86%
Hold
14%

Financial data from Avinger, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
7.26 7.26
6% 6%
100%
- Direct Costs 5.74 5.74
6% 6%
79%
1.52 1.52
34% 34%
21%
- Selling and Administrative Expenses 15 15
9% 9%
204%
- Research and Development Expense 4.20 4.20
7% 7%
58%
-17 -17
10% 10%
-237%
- Depreciation and Amortization 0.32 0.32
14% 14%
4%
EBIT (Operating Income) EBIT -18 -18
10% 10%
-241%
Net Profit -17 -17
7% 7%
-239%

In millions USD.

Don't miss a Thing! We will send you all news about Avinger, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Avinger, Inc. Stock News

Neutral
GlobeNewsWire
6 months ago
SANTA CLARA, CALIFORNIA, Feb. 17, 2025 (GLOBE NEWSWIRE) -- On February 10, 2025, Avinger, Inc., a Delaware Corporation (“Avinger” or the “Company”), entered into a general assignment for the benefit of creditors (the “Assignment”) in favor of Avinger (assignment for the benefit of creditors), LLC, a California limited liability company (the “Assignee”).

Company Profile

Avinger, Inc. manufactures catheter devices used to treat vascular diseases. It designs, manufactures and sells image-guided, catheter-based systems that are used by physicians to treat patients with peripheral artery disease. Its products include Pantheris, Lightbox, Ocelot, Ocelot MVRX, Ocelot PIXL, Pantheris, Wildcat, Juicebox and Kittycat 2. The company offers its products to interventional cardiologists, vascular surgeons, and interventional radiologists. Avinger was founded by John B. Simpson and Himanshu N. Patel on March 8, 2007 and is headquartered in Redwood City, CA.

Head office United States
CEO Jeffrey Soinski
Employees 71
Founded 2007
Website avinger.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today